CytomX Therapeutics, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-98.3% -$37M
$663K
R&D↑+43.6% +$6M
$21M
D&A↓-80.0% -$400K
$100K
Operating Income↓-483.6% -$20M
$-16M
EBITDA↓-99.4% -$18M
$100K
Interest Expense
—
Interest Income↑+15.9% +$203K
$1M
Other Income/Expense↑+171.4% +$12K
$5K
Pretax Income↓-344.5% -$20M
$-14M
Tax Provision↓-12.9% -$8K
$54K
Net Income↓-348.1% -$20M
$-14M
Operating Margin↓-276.7pts
-264.4%
Net Margin↓-255.8pts
-238.6%
Effective Tax Rate↓-1.5pts
-0.4%
Deferred Tax Liabilities
—
ETR (Continuing Operations)↓-2.1pts
-1.4%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-20.4pts
-1.4%
Operating Lease Cost
$1M
Revenue YoY Variation↓-141.4pts
-98.3%
Income YoY Variation↓-515.2pts
-483.6%
Revenue QoQ Variation↓-102.8pts
-88.9%
Income QoQ Variation↓-1274.8pts
-1126.1%